NantOmics

NantOmics is a biotechnology company based in Culver City, California, which provides molecular diagnostic products for personalized cancer treatment. It is part of the NantWorks network, a corporation consisting of different startups in the medical and health industry.[1]

NantOmics, LLC
Limited liability
IndustryBiotechnology, molecular diagnostics
Founded2013
FounderPatrick Soon-Shiong
Headquarters,
ProductsmMlecular diagnostic products

History

NantOmics was founded in 2013 by billionaire Patrick Soon-Shiong. In 2015 NantOmics bought the cancer diagnostics company OncoPlex Dx.[2] In 2017 the company acquired the consumer genomics startup Genos.[3]

In 2016 the company's revenue was about $58.3 million with a net loss of about $72.00 million.[4] As of 2017, the company is classified as a unicorn startup with an estimated value of over $1 billion.[5][6]

Products

GPS Cancer involves sequencing of the genome and RNA of tumor cells in comparison to normal cells from the same individual in order to develop personalized treatments.[7] About 327,000 cancer patients participated in a GPS cancer pilot project in 2017.[8]

References

  1. "NantOmics, LLC: Private Company Information - Bloomberg". www.bloomberg.com. Retrieved 2018-03-30.
  2. "NantOmics Acquires OncoPlex Diagnostics, an Accredited Proteomics Diagnostic Laboratory". Retrieved 2018-03-30.
  3. "Bio-IT World". www.bio-itworld.com. Retrieved 2018-03-30.
  4. "NantHealth files for $92 million IPO". MobiHealthNews. 2016-05-09. Retrieved 2018-03-30.
  5. "The unicorns of SoCal Tech: 15 startups valued at more than $1B". Built In Los Angeles. Retrieved 2019-04-23.
  6. "Unicorn startups: Billion-dollar startups (2018 updated list)". Startups News | Tech News. 2018-04-08. Retrieved 2019-04-23.
  7. "GPS Cancer Overview". GPS Cancer. Retrieved 2018-03-30.
  8. "NantHealth Reports 16% Increase in 2017 First Quarter Total Net Revenue; SaaS Revenue Rose 11% and GPS Adoption Continues to Climb". Retrieved 2018-03-30.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.